Corvus Pharmaceuticals CRVS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's total liabilities?
- Corvus Pharmaceuticals (CRVS) reported total liabilities of $12.52M in Q1 2026.
- How has Corvus Pharmaceuticals's total liabilities changed year-over-year?
- Corvus Pharmaceuticals's total liabilities increased by 23.8% year-over-year, from $10.11M to $12.52M.
- What is the long-term trend for Corvus Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total liabilities has grown at a -5.8% compound annual growth rate (CAGR), from $13.38M to $9.91M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.